Diabetes Block Stimulation Neuromodulation Therapy
Award amount
$299,048Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- RESHAPE LIFESCIENCES INC
- Proposal award date
- 2019-08-01
- Contract end date
- 2020-07-31
- UEI
- YL7CYVSRUN55
- Solicitation number
- PA18-574
- Topic code
- NIDDK
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Diabetic Targeted Dual Neuromodulation Parametric Optimization
- High-definition Endoscopic Ultrasound Navigation for Targeted Dual Neuromodulation Therapy
- Hypoglycemia Vagal Nerve Stimulation Therapy (HVNS Therapy)
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
4 SBIR/STTR records share this UEI (2019–2024). Reported award amounts total $1,276,149. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services